Found: 20
Select item for more details and to access through your institution.
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non‐valvular atrial fibrillation and heart failure.
- Published in:
- ESC Heart Failure, 2019, v. 6, n. 1, p. 10, doi. 10.1002/ehf2.12365
- By:
- Publication type:
- Article
Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non‐valvular atrial fibrillation and type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 9, p. 2107, doi. 10.1111/dom.13787
- By:
- Publication type:
- Article
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 4, p. 329, doi. 10.2165/00019053-200927040-00005
- By:
- Publication type:
- Article
Rivaroxaban versus apixaban in non‐valvular atrial fibrillation patients with end‐stage renal disease or receiving dialysis.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 4, p. 328, doi. 10.1111/ejh.13383
- By:
- Publication type:
- Article
Comparative risk of major bleeding with rivaroxaban and warfarin: Population‐based cohort study of unprovoked venous thromboembolism.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 2, p. 143, doi. 10.1111/ejh.13185
- By:
- Publication type:
- Article
Observation management of pulmonary embolism and agreement with claims-based and clinical risk stratification criteria in United States patients: a retrospective analysis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Anemia in Chronic Kidney Disease: An Opportunity and Challenge for Disease Management.
- Published in:
- Disease Management, 2008, v. 11, n. 1, p. 47, doi. 10.1089/dis.2008.111733
- By:
- Publication type:
- Article
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis.
- Published in:
- Thrombosis Journal, 2020, v. 18, n. 1, p. 1, doi. 10.1186/s12959-020-00219-w
- By:
- Publication type:
- Article
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2021, v. 51, n. 2, p. 349, doi. 10.1007/s11239-020-02199-0
- By:
- Publication type:
- Article
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2019, v. 48, n. 3, p. 366, doi. 10.1007/s11239-019-01898-7
- By:
- Publication type:
- Article
Agreement between coding schemas used to identify bleeding‐related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients.
- Published in:
- Clinical Cardiology, 2018, v. 41, n. 1, p. 119, doi. 10.1002/clc.22861
- By:
- Publication type:
- Article
Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
- Published in:
- Pharmacotherapy, 2019, v. 39, n. 2, p. 196, doi. 10.1002/phar.2213
- By:
- Publication type:
- Article
Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis.
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2020, v. 26, p. 1, doi. 10.1177/1076029620954910
- By:
- Publication type:
- Article
Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis.
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2019, v. 25, p. 1, doi. 10.1177/1076029619868535
- By:
- Publication type:
- Article
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism.
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2018, v. 24, n. 4, p. 575, doi. 10.1177/1076029618758955
- By:
- Publication type:
- Article
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
- Published in:
- Clinical & Applied Thrombosis/Hemostasis, 2017, v. 23, n. 7, p. 830, doi. 10.1177/1076029616661415
- By:
- Publication type:
- Article
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
- Published in:
- Kidney International, 2008, v. 74, n. 12, p. 1588, doi. 10.1038/ki.2008.489
- By:
- Publication type:
- Article
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2018, v. 46, n. 3, p. 339, doi. 10.1007/s11239-018-1695-1
- By:
- Publication type:
- Article
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
- Published in:
- Journal of the American Heart Association, 2018, v. 7, n. 8, p. 1, doi. 10.1161/JAHA.118.008643
- By:
- Publication type:
- Article